在线观看亚洲专区,伊色综合久久之综合久久,天天综合天天

<strike id="uys8c"></strike>

中文站

Careers | Investors | Patients and HCPS | Contact us

Careers Investors Patients and HCPS Contact us

Search

# Popular search #

Diabetes Oncology Medical Devices

Company News

Company News Exhibitions Activities

All news 2025 2024 2023 2022 2021 2018

Gan & Lee Pharmaceuticals Announced Positive Phase 1 Results for Its Oral GLP-1 Receptor Agonist GZR18 Tablet in Healthy Participants, Demonstrating 4.16% Weight Reduction in Two Weeks
Gan & Lee 2024-11-13
ObesityWeek?? 2024 | Gan & Lee Pharmaceuticals Orally Presents Phase 2b Clinical Data for GZR18 Injection in Chinese Overweight and Obese Adults
Gan & Lee 2024-11-12
Malaysian Deputy Prime Minister Attends Groundbreaking Ceremony of Gan & Lee Pharmaceuticals' Partner Factory
Gan & Lee 2024-11-11
Gan & Lee Pharmaceuticals Shines at CPHI Worldwide 2024 in Milan
Gan & Lee 2024-10-17
Gan & Lee Pharmaceuticals’ Three Innovative Drugs: GZR18 Injection, GZR4 Injection, and GZR101 Injection Achieve Primary Endpoints in Phase 2 Clinical Studies
Gan & Lee 2024-10-16
[EASD 2024 Highlights] Once-weekly Insulin GZR4
Gan & Lee 2024-09-29

< 1 2 3 4 5 6 7 8 ... 14 15 >

Our websites

Gangan Technology

You are now leaving the Gan & Lee website.

The site you are about to visit is maintained by a third party who is responsible for its content.
This link is provided on the Gan & Lee website as a service to our visitors. Gan & Lee is not responsible for the privacy policy of any third-party websites. Gan & Lee encourages visitors to read the privacy policy of every website that you may visit.

Continue Back

Search

Subscribe